Showing 7351-7360 of 8649 results for "".
- United Kingdom First to Grant License for Teva’s Ophthalmology Biosimilar Ongavia (Ranibizumab)https://modernod.com/news/united-kingdom-first-to-grant-license-for-tevas-ophthalmology-biosimilar-ongavia-ranibizumab/2480870/Teva Pharmaceutical announced that the UK Medicines & Healthcare Regulatory Agency (MHRA) has granted a licence for Ongavia, a biosimilar to Lucentis (ranibizumab). The United Kingdom is the first country in Europe to authorize commercialization of Ongavia for
- Visionix and Right MFG to Enter a Long-Term Strategic Partnershiphttps://modernod.com/news/visionix-and-right-mfg-to-enter-a-long-term-strategic-partnership/2480863/Visionix, formerly Luneau Technology, and Japan-based Right MFG announced today that they have entered a long-term strategic partnership agreement with the aim of accelerating growth for both companies. Financial terms of the deal were not disclosed.
- iSTAR Medical Expands Commercial Rollout With First MINIject Surgeries in Switzerlandhttps://modernod.com/news/istar-medical-expands-commercial-rollout-with-first-miniject-surgeries-in-switzerland/2480852/iSTAR Medical announced that it has continued its commercial rollout expansion for MINIject® to Switzerland. MINIject® is iSTAR Medical’s MIGS implant and currently the only commercially available supraciliary MIGS device, according to the company. Swiss patients with open-angl
- Nova Eye Medical Reports Canaloplasty Data Demonstrating Sustained Reduction in IOP with iTrackhttps://modernod.com/news/nova-eye-medical-reports-canaloplasty-data-demonstrating-sustained-reduction-in-iop-with-itrack/2480849/Nova Eye Medical reported the recent publication of three investigator-led, retrospective case series which evaluated the long-term effectiveness of canaloplasty in patients with open-angle glaucoma (OAG) over 36- and 48-month periods, and in post-keratoplasty patients. Performed b
- Bausch + Lomb Presents Data from Second Pivotal Phase 3 Trial of Investigational Treatment NOV03https://modernod.com/news/bausch-lomb-presents-data-from-second-pivotal-phase-3-trial-of-investigational-treatment-nov03-at-arvo/2480837/Bausch + Lomb and Novaliq announced that data from the second pivotal phase 3 trial (MOJAVE) of investigational treatment NOV03 (perfluorohexyloctane) were presented at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting. NOV03 is being investigated as a first-in-c
- RetinAI Receives FDA Clearance for Discovery Image Management Platform for Ophthalmologyhttps://modernod.com/news/retinai-receives-fda-clearance-for-discovery-image-management-platform-for-ophthalmology/2480826/RetinAI Medical AG announced it has received FDA 510(k) clearance for RetinAI Discovery, the company’s image and data management platform for interoperability across the clinical and clinical study ecosystems in ophthalmology. The Discovery platform can be
- Nicox Presents Phase 2 Results on NCX 4251 and New Nonclinical Evidence of Improved Hemodynamic and Retinal Cell Physiology on NCX 470https://modernod.com/news/nicox-presents-phase-2-results-on-ncx-4251-and-new-nonclinical-evidence-of-improved-hemodynamic-and-retinal-cell-physiology-on-ncx-470/2480822/Nicox SA announced poster presentations highlighting the effect of NCX 4251 in patients with dry eye disease as well as new nonclinical evidence of neuroprotective activity on NCX 470 at the Association for Research in Vision and Ophthalmology (ARVO) 2022 annual meeting, one of the key scien
- Verana Health Report Shows a More Than 80% Glaucoma Surgery Uptake Over 8-Year Periodhttps://modernod.com/news/verana-health-unveils-annual-ophthalmic-industry-report-that-shows-a-more-than-80-glaucoma-surgery-uptake-over-8-year-period-1/2480818/Verana Health announced the release of its American Academy of Ophthalmology IRIS Registry (Intelligent Research in Sight) Industry Report for 2021 at the ASCRS annual meeting. The report provides 8 years of detailed ophthalmic insights generated through analysis of the data contained i
- Ophthalmic Organizations Release Position Statement on Multidose Topical Medications for Ophthalmic Surgeryhttps://modernod.com/news/ophthalmic-organizations-release-position-statement-on-multidose-topical-medications-for-ophthalmic-surgery/2480798/The American Society of Cataract and Refractive Surgery (ASCRS), the American Academy of Ophthalmology (AAO), the American Glaucoma Society (AGS) and the Outpatient Ophthalmic Surgery Society (OOSS) have jointly released a new position statement with recommendations for reducing topical drug wast
- Théa Introduces iVIZIA OTC Eye Care Products in UShttps://modernod.com/news/thea-introduces-ivizia-otc-eye-care-products-in-us/2480796/Théa Pharma announced the availability of the iVIZIA line of over-the-counter (OTC) eye care products in the United States. The iVIZIA OTC product line includes lubricating eye drops, lubricating eye gel, and three options for daily hygiene of sensitive eyelids. iVIZIA